Private Equity Firm Healthcare

Ampersand Capital Partners

Boston, Massachusetts, United States

Founded in 1988, Ampersand is a middle-market private equity firm with about $3 billion in assets under management dedicated to growth-oriented investments in the healthcare sector. The firm has offices in Boston, Amsterdam, and London and partners with portfolio management teams to build value and drive long-term performance.

Focus Areas
Healthcare private equity, Healthcare and life sciences investing

Tracked deals

61

61 tracked deals across 2019-2026.

Recent pace

3

3 tracked deals announced in the last 12 months.

Deal mix

Addon

22 addon · 16 growth capital · 11 buyout

Ampersand Capital Partners Acquisition Volume by Year

Last 8 years

Acquisition volume by year Annual acquisition counts for the last 8 years for Ampersand Capital Partners. 8 2019 9 2020 7 2021 11 2022 7 2023 12 2024 4 2025 ~5 est. 3 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

Showing the 12 most recent of 61 tracked deals for Ampersand Capital Partners.

  • Corten Capital and Ampersand Capital Partners Acquire Beacon Intelligence from Hanson Wade Group
    June 30, 2026
    Buyer
    Corten Capital, Ampersand Capital Partners
    Target
    Beacon Intelligence
    Seller
    Hanson Wade Group
    Industry
    Data & Analytics
    Location
    United Kingdom
    Type
    Buyout

    Corten Capital and Ampersand Capital Partners have completed the acquisition of Beacon Intelligence from the Hanson Wade Group, backed by Graphite Capital. Corten Capital becomes the majority owner while Ampersand invests alongside Corten as a minority co-investor to support Beacon’s next phase of growth as an independent life sciences R&D intelligence platform.

  • Ampersand Capital Partners Acquires Purna Pharmaceuticals
    February 12, 2026
    Buyer
    Ampersand Capital Partners
    Target
    Purna Pharmaceuticals
    Seller
    Creafund
    Industry
    Healthcare Services
    Location
    Flemish Region, Belgium
    Type
    Buyout

    Ampersand Capital Partners acquired Purna Pharmaceuticals, a Belgian contract development and manufacturing provider for liquid and semi-solid pharmaceutical dosage forms. The investment is intended to enable collaboration with Ampersand portfolio company MedPharm to build a trans-Atlantic topical and transdermal drug formulation and manufacturing partnership for global pharmaceutical clients.

  • Gannet BioChem Acquires Laysan Bio
    January 22, 2026
    Buyer
    Gannet BioChem, Ampersand Capital Partners
    Target
    Laysan Bio
    Industry
    Biotechnology
    Location
    Alabama, United States
    Type
    Addon

    Gannet BioChem, a PE-backed specialty CDMO, has acquired Laysan Bio, a maker of activated polyethylene glycol (PEG) reagents based in Arab, Alabama. The add-on expands Gannet BioChem's activated polymer and bioconjugation capabilities, strengthening its ability to support partners from early development through GMP manufacturing.

  • Ampersand Capital Partners Acquires CurTec
    July 21, 2025
    Buyer
    Ampersand Capital Partners
    Target
    CurTec Group B.V.
    Seller
    Bencis Capital Partners, CurTec management
    Industry
    Packaging
    Location
    North Brabant, Netherlands
    Type
    Buyout

    Ampersand Capital Partners has acquired CurTec Group B.V., a Netherlands-based manufacturer of high-performance plastic packaging for pharmaceutical and specialty chemical applications, from Bencis Capital Partners in partnership with CurTec management. The deal positions Ampersand to scale CurTec's U.S. footprint, accelerate product innovation, and expand capacity and commercial capabilities to serve pharma and specialty chemicals customers globally.

  • Julius Clinical (Ampersand-backed) Merges with Peachtree BioResearch Solutions
    May 14, 2025
    Buyer
    Julius Clinical, Ampersand Capital Partners
    Target
    Peachtree BioResearch Solutions
    Industry
    Healthcare Services
    Location
    Georgia, United States
    Type
    Addon

    Julius Clinical, a Netherlands-based CRO supported by Ampersand Capital Partners, has merged with Peachtree BioResearch Solutions, a specialized CNS CRO based in Georgia, USA. The merger creates a larger, fully integrated global CRO with expanded CNS capabilities and enhanced access across Europe and North America.

  • Ampersand Capital Partners Makes Growth Investment in Lexington Medical
    April 17, 2025
    Buyer
    Ampersand Capital Partners
    Target
    Lexington Medical
    Industry
    Medical Devices
    Location
    Massachusetts, United States
    Type
    Growth capital

    Ampersand Capital Partners has made a strategic growth investment in Lexington Medical, a Bedford, Massachusetts-based designer and manufacturer of minimally invasive surgical stapling devices. The investment will support Lexington's product innovation, smart manufacturing initiatives, and global market expansion while bolstering the company's US-based manufacturing and talent base.

  • NanoImaging Services Acquires Proteos
    January 5, 2025
    Buyer
    NanoImaging Services, Ampersand Capital Partners
    Target
    Proteos, Inc.
    Industry
    Biotechnology
    Location
    Michigan, United States
    Type
    Addon

    NanoImaging Services (NIS), a cryo-electron microscopy services provider backed by Ampersand Capital Partners, has acquired Proteos, Inc., a Kalamazoo-based CRO specializing in recombinant protein and antibody production. The add-on acquisition integrates Proteos’ protein production capabilities with NIS’s cryo-EM services to create an end-to-end offering for structure-based drug discovery and protein production workflows.

  • Ampersand Capital Partners Makes Growth Investment in VIVEbiotech
    December 4, 2024
    Buyer
    Ampersand Capital Partners
    Target
    VIVEbiotech
    Industry
    Biotechnology
    Location
    Gipuzkoa, Spain
    Type
    Growth capital

    Ampersand Capital Partners has made a growth equity investment in VIVEbiotech to support expansion of the company’s lentiviral vector development and GMP manufacturing capabilities in San Sebastián, Gipuzkoa, Spain. The investment will fund capacity growth and execution of VIVEbiotech’s pipeline of customer projects for cell and gene therapy developers, and industry veteran Dr. Stefan Beyer has been named Chairman.

  • Ampersand Capital Partners Acquires Nektar Therapeutics' PEG Reagent Manufacturing Business, Launches Gannet BioChem
    December 2, 2024
    Buyer
    Ampersand Capital Partners
    Target
    Gannet BioChem
    Seller
    Nektar Therapeutics
    Industry
    Biotechnology
    Location
    Alabama, United States
    Type
    Divestiture

    Ampersand Capital Partners has completed the acquisition of Nektar Therapeutics' PEGylation reagent manufacturing business and launched the new Ampersand portfolio company, Gannet BioChem, operating from a 124,000 sq. ft. FDA‑inspected facility in Huntsville, Alabama. The transaction represents a divestiture by Nektar and creates an independent specialty CDMO focused on development, scaling, and GMP production of polyethylene glycol (PEG) reagents for clinical and commercial biopharmaceutical customers.

  • GHO Capital and Ampersand Acquire Avid Bioservices for $1.1 Billion
    November 7, 2024
    Buyer
    GHO Capital Partners LLP, Ampersand Capital Partners
    Target
    Avid Bioservices
    Seller
    Avid Bioservices stockholders
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    GHO Capital Partners and Ampersand Capital Partners have completed the acquisition of Avid Bioservices, a dedicated biologics CDMO, in an all-cash transaction valued at approximately $1.1 billion. The transaction takes Avid private (shareholders received $12.50 per share) and positions the company for capability expansion, geographic reach and accelerated growth under the new PE ownership.

  • P95 BV Acquires Assign DMB
    September 5, 2024
    Buyer
    P95 BV, Ampersand Capital Partners
    Target
    Assign DMB
    Industry
    Healthcare Services
    Location
    Tyrol, Austria
    Type
    Addon

    P95 BV, a Belgium-based epidemiology and clinical solutions provider backed by Ampersand Capital Partners, has acquired Assign DMB, an Innsbruck, Austria-based clinical research organisation specializing in clinical data management and biostatistics. The deal expands P95's capabilities and capacity to run clinical and non-interventional studies—particularly in vaccines and infectious diseases—and broadens its presence in Europe and globally.

  • Leinco Technologies Acquires QED Biosciences from Genovis
    September 3, 2024
    Buyer
    Leinco Technologies, Ampersand Capital Partners
    Target
    QED Biosciences
    Seller
    Genovis
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Addon

    Leinco Technologies, a portfolio company backed by Ampersand Capital Partners, has acquired Genovis-owned QED Biosciences to expand its catalog of antibodies, recombinant proteins and IVD raw materials. The deal transfers Genovis' antibody business to Leinco and strengthens Leinco's antibody development and IVD support capabilities for research and diagnostics customers worldwide.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 23 tracked deals by Ampersand Capital Partners. Healthcare Services Buyers & Acquisitions 20 tracked deals by Ampersand Capital Partners. Medical Devices Buyers & Acquisitions 9 tracked deals by Ampersand Capital Partners. Pharmaceuticals Buyers & Acquisitions 4 tracked deals by Ampersand Capital Partners. Acquisitions in Massachusetts 7 tracked deals by Ampersand Capital Partners. Acquisitions in California 6 tracked deals by Ampersand Capital Partners. Acquisitions in New Jersey 4 tracked deals by Ampersand Capital Partners. Acquisitions in Alabama 2 tracked deals by Ampersand Capital Partners.

Selling a company? Get in front of buyers like Ampersand Capital Partners

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →